| 1. |
- Fjeldså, Jon, et al.
(author)
-
Description of two new Cisticola species endemic to the marshes of the Kilombero floodplain of southwestern Tanzania
- 2021
-
In: Ibis. - : Wiley. - 0019-1019 .- 1474-919X. ; 163:4, s. 1330-1354
-
Journal article (peer-reviewed)abstract
- The presence of two undescribed cisticola warblers in the marshes of the Kilombero floodplain in central Tanzania has been known since the 1980s and these putative new species have been illustrated in field guides on African birds, although with no formal name. Here we name both species, based on two museum specimens collected in 1961 and recently detected in a museum collection. We use these specimens to provide formal descriptions of each form and, using DNA sequence data extracted from these specimens, we place them in a broad phylogenetic framework for the genus Cisticola. The phylogenetic placement indicates that one of the new species is nested within a group of plain-backed duetting cisticolas and the other within the streak-backed marsh cisticolas. We use our own and public recordings to characterize the vocal repertoire of each of these new species and compare song characteristics with other members of their respective clades. Dating of nodes in the molecular phylogeny suggests that both cisticolas endemic to the Kilombero became isolated and diverged from their sister-species between 2.5 and 3.5 million years ago, long after the formation of the Eastern Arc Mountains and the Malawi Rift. We propose that both species should be classified as globally endangered, owing to immense anthropogenic pressures on the floodplain, as documented in several publications and by a recent Ramsar Advisory Mission.
|
|
| 2. |
- Mellberg, Tomas, et al.
(author)
-
HIV-1 low copy viral sequencing-a prototype assay
- 2016
-
In: Infectious Diseases. - : Informa UK Limited. - 2374-4235 .- 2374-4243. ; 48:6, s. 472-478
-
Journal article (peer-reviewed)abstract
- In HIV-1 patients with low viral burden, sequencing is often problematic, yet important. This study presents a sensitive, sub-type independent system for sequencing of low level viremia. Sequencing data from 32 HIV-1 infected patients with low level viremia were collected longitudinally. A combination of ViroSeq HIV-1 Genotyping System and an in-house nesting protocol was used. Eight sub-types were represented. The success-rate of amplification of both PR and RT in the same sample was 100% in samples with viral loads above 100 copies/ml. Below 100 copies/ml, this study managed to amplify both regions in 7/13 (54%) samples. The assays were able to amplify either PR or RT in all sub-types included but one sub-type A specimen. In conclusion, this study presents a promising, simple assay to increase the ability to perform HIV-1 resistance testing at low level viremia. This is a prototype assay and the method needs further testing to evaluate clinical performance. © 2016 Society for Scandinavian Journal of Infectious Diseases.
|
|
| 3. |
|
|
| 4. |
- Ostergaard, Mikkel, et al.
(author)
-
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
- 2023
-
In: Annals of the Rheumatic Diseases. - : BMJ PUBLISHING GROUP. - 0003-4967 .- 1468-2060. ; 82:10, s. 1286-1295
-
Journal article (peer-reviewed)abstract
- Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Methods Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naive early RA with moderate-severe disease activity were randomised 1:1:1:1 to methotrexate combined with (1) active conventional therapy: oral prednisolone (tapered quickly, discontinued at week 36) or sulfasalazine, hydroxychloroquine and intra-articular glucocorticoid injections in swollen joints; (2) certolizumab pegol; (3) abatacept or (4) tocilizumab. Coprimary endpoints were week 48 Clinical Disease Activity Index (CDAI) remission (CDAI <= 2.8) and change in radiographic van der Heijde-modified Sharp Score, estimated using logistic regression and analysis of covariance, adjusted for sex, anticitrullinated protein antibody status and country. Bonferroni's and Dunnet's procedures adjusted for multiple testing (significance level: 0.025). Results Eight hundred and twelve patients were randomised. Adjusted CDAI remission rates at week 48 were: 59.3% (abatacept), 52.3% (certolizumab), 51.9% (tocilizumab) and 39.2% (active conventional therapy). Compared with active conventional therapy, CDAI remission rates were significantly higher for abatacept (adjusted difference +20.1%, p<0.001) and certolizumab (+13.1%, p=0.021), but not for tocilizumab (+12.7%, p=0.030). Key secondary clinical outcomes were consistently better in biological groups. Radiographic progression was low, without group differences. Conclusions Compared with active conventional therapy, clinical remission rates were superior for abatacept and certolizumab pegol, but not for tocilizumab. Radiographic progression was low and similar between treatments.
|
|
